An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Nature

• Publication date

  2003-11-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature02099PMID 14578911
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.

  2004cited by this paper
• Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.

  2003cited by this paper
• MicroRNAs and other tiny endogenous RNAs in C. elegans.

  2003cited by this paper
• A micrococcal nuclease homologue in RNAi effector complexes

  2003cited by this paper
• An NS3 Serine Protease Inhibitor Abrogates Replication of Subgenomic Hepatitis C Virus RNA*

  2003cited by this paper
• Hairpin RNAs and Retrotransposon LTRs Effect RNAi and Chromatin-Based Gene Silencing

  2003cited by this paper
• 294 Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis

  2003cited by this paper
• A genome-wide screen identifies 27 genes involved in transposon silencing in C. elegans.

  2003cited by this paper
• Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

  2003cited by this paper
• RNA Helicase MUT-14-Dependent Gene Silencing Triggered in C. elegans by Short Antisense RNAs

  2002cited by this paper
• Regulation of Heterochromatic Silencing and Histone H 3 Lysine-9 Methylation by RNAi

  2002cited by this paper
• Treatment of chronic hepatitis C: A systematic review

  2002cited by this paper
• New therapeutic strategies for hepatitis C

  2002cited by this paper
• Small RNAs Correspond to Centromere Heterochromatic Repeats

  2002cited by this paper
• The role of RNA editing by ADARs in RNAi.

  2002cited by this paper
• The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DExH-box helicase to direct RNAi in C. elegans.

  2002cited by this paper
• Treatment of chronic hepatitis C: A systematic review

  2002cited by this paper
• Hepatitis C therapeutics: current status and emerging strategies

  2002cited by this paper
• RNA Silencing: The Genome's Immune System

  2002cited by this paper
• Transcriptional and posttranscriptional gene silencing are mechanistically related

  2001cited by this paper
• Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease.

  2001cited by this paper
• Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.

  2001cited by this paper
• Hepatitis C virus replication in mice with chimeric human livers

  2001cited by this paper
• On the role of RNA amplification in dsRNA-triggered gene silencing.

  2001cited by this paper
• Creation of low-copy integrated transgenic lines in Caenorhabditis elegans.

  2001cited by this paper
• Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

  2000cited by this paper
• NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain.

  2000cited by this paper
• RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

  2000cited by this paper
• Functional genomic analysis of C. elegans chromosome I by systematic RNA interference

  2000cited by this paper
• Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.

  2000cited by this paper
• Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties.

  2000cited by this paper
• Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo

  2000cited by this paper
• Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference.

  2000cited by this paper
• Variation in the reversibility of evolution

  2000cited by this paper
• Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

  1999cited by this paper
• The rde-1 gene, RNA interference, and transposon silencing in C. elegans.

  1999cited by this paper
• Mut-7 of C. elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD.

  1999cited by this paper
• Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line

  1999cited by this paper
• Ballistic transformation of Caenorhabditis elegans.

  1999cited by this paper
• Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption.

  1999cited by this paper
• Solution Structure of Substrate-based Ligands When Bound to Hepatitis C Virus NS3 Protease Domain*

  1999cited by this paper
• Specific interference by ingested dsRNA

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Peptide-based inhibitors of the hepatitis C virus serine protease.

  1998cited by this paper
• Hepatitis C

  1998cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Product inhibition of the hepatitis C virus NS3 protease.

  1998cited by this paper
• Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

  1998cited by this paper
• Chromatin silencing and the maintenance of a functional germline in Caenorhabditis elegans.

  1998cited by this paper
• Hepatitis C.

  1998cited by this paper
• Isolation of actin‐associated proteins from Caenorhabditis elegans oocytes and their localization in the early embryo

  1997cited by this paper
• RNA-Mediated Virus Resistance: Role of Repeated Transgenes and Delineation of Targeted Regions.

  1996cited by this paper
• Transposase is the only nematode protein required for in vitro transposition of Tc1.

  1996cited by this paper
• Suppression of Virus Accumulation in Transgenic Plants Exhibiting Silencing of Nuclear Genes.

  1996cited by this paper
• An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

  1990cited by this paper
• Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

  1989cited by this paper
• Evidence for a transposon in Caenorhabditis elegans.

  1983cited by this paper
• On the size of the active site in proteases. I. Papain.

  1967cited by this paper
• Nonlinear limits to the information capacity of optical ® bre communications

  year unknowncited by this paper

• Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D

  2025cites this paper
• Unraveling the therapeutic landscape of approved non-peptide macrocycles

  2025influential citation
• Structure-guided design and development of cyclic peptide allosteric activators of Polycomb Repressive Complex 2

  2025cites this paper
• Harnessing Viral Proteases for Cellular and Molecular Engineering

  2025cites this paper
• Advances in the Synthesis of Cyclopropylamines.

  2025cites this paper
• Design of Hepatitis C Protease Inhibitors Based on Knottin Fold

  2024cites this paper
• Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy

  2024cites this paper
• The coming of age of cyclic peptide drugs: an update on discovery technologies

  2024cites this paper
• Macrocyclic Oxindole Peptide Epoxyketones—A Comparative Study of Macrocyclic Inhibitors of the 20S Proteasome

  2024cites this paper
• Macrocyclic-based strategy in drug design: From lab to the clinic.

  2024cites this paper
• Proline Analogues.

  2024cites this paper
• Halogenated Secondary Metabolites from Higher Plants: Potent Drug Candidates for Chikungunya Using in silico Approaches

  2024cites this paper
• The potential inhibitory mechanism of EGCG against the Chikungunya virus targeting non-structural protein 2 through molecular dynamics simulation

  2024cites this paper
• Cyclization by Intramolecular Suzuki‐Miyaura Cross‐Coupling–A Review

  2024cites this paper
• On the origins of SARS-CoV-2 main protease inhibitors.

  2024cites this paper
• Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study

  2023cites this paper
• Successes in antiviral drug discovery: a tribute to Nick Meanwell

  2023cites this paper
• Reflections on a 40-year career in drug design and discovery

  2023cites this paper
• NMR Spectroscopy Can Help Accelerate Antiviral Drug Discovery Programs.

  2023cites this paper
• Development of covalent inhibitors: Principle, design, and application in cancer

  2023cites this paper
• Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus

  2023cites this paper
• Antivirals against HCV infection: the story thus far.

  2022cites this paper
• Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells

  2022cites this paper
• Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice

  2022influential citation
• Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site

  2022cites this paper
• Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe

  2022cites this paper
• Microbial Natural Products with Antiviral Activities, Including Anti-SARS-CoV-2: A Review

  2022cites this paper
• Special Collection: A pioneer in antiviral drug discovery and development: Commemorating John Martin Review

  2022cites this paper
• Hépatites virales

  2022cites this paper
• Cationic Geminoid Peptide Amphiphiles Inhibit DENV2 Protease, Furin, and Viral Replication

  2022cites this paper
• Breakthroughs in hepatitis C research: from discovery to cure

  2022cites this paper
• Synthesis of 1-[1-(Amino)cyclopropyl]ketones by Tandem Reaction Involving Vinyl Selenium Salt

  2022cites this paper
• HCV genotype-specific drug discovery through structure-based virtual screening

  2022cites this paper
• Defining and navigating macrocycle chemical space†

  2021cites this paper
• Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode

  2021cites this paper
• On the Possibility of Eradicating Hepatitis C in Russia

  2021cites this paper
• Insights into the Role of Tick Salivary Protease Inhibitors during Ectoparasite–Host Crosstalk

  2021cites this paper
• Antiviral phytochemicals as potent inhibitors against NS3 protease of dengue virus

  2021cites this paper
• On the Possibility of Eradicating Hepatitis C in Russia

  2021cites this paper
• DNA-RNA

  2021cites this paper
• Using tea nanoclusters as β-lactamase inhibitors to cure multidrug-resistant bacterial pneumonia: A promising therapeutic strategy by Chinese materioherbology

  2021cites this paper
• A Focus on Severe Acute Respiratory Syndrome ( SARS ) Coronavirus ( SARS‐CoVs ) 1 and 2

  2021cites this paper
• Curing Hepatitis C with Direct‐Acting Antiviral Therapy

  2021cites this paper
• Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

  2021cites this paper
• Molecular Biology of Hepatitis Viruses

  2020cites this paper
• GSK2818713, a novel biphenylene scaffold-based Hepatitis C NS5A replication complex inhibitor with broad genotype coverage.

  2020cites this paper
• Viruses and Human Cancer

  2020cites this paper
• Biosensor Applications for Viral and Bacterial Disease Diagnosis

  2020cites this paper
• Discovery and Chemical Development of Grazoprevir: An HCV NS3/4a Protease Inhibitor for the Treatment of the Hepatitis C Virus Infection

  2020cites this paper
• Supercomputer-aided Drug Repositioning at Scale: Virtual Screening for SARS-CoV-2 Protease Inhibitor

  2020cites this paper
• Integrating Evolution of Drug Resistance into Drug Discovery

  2020cites this paper
• Zellkultursysteme als Basis der Therapieentwicklung für chronische Hepatitis C

  2020influential citation
• Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships

  2020cites this paper
• Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities

  2020cites this paper
• Gain-of-function assay for SARS-CoV-2 Mpro inhibition in living cells

  2020cites this paper
• Modulators of calpain activity: inhibitors and activators as potential drugs

  2020cites this paper
• Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.

  2020cites this paper
• Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure – Activity Relationships

  2020cites this paper
• Traitement de l’infection par le virus de l’hépatite C (VHC)

  2020cites this paper
• Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure – Activity Relationships

  2020cites this paper
• An optimal scheme to boost immunity and suppress viruses for HIV by combining a phased immunotherapy with the sustaining antiviral therapy.

  2020cites this paper
• Determination of Protein Structure and Dynamics by NMR

  2020cites this paper
• The 2020 Nobel Prize in Physiology or Medicine.

  2020cites this paper
• A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus

  2020cites this paper
• Treatment of hepatitis C virus infection.

  2020cites this paper
• Biotechnological, biomedical, and agronomical applications of plant protease inhibitors with high stability: A systematic review.

  2020cites this paper
• HCV Replicon Systems: Workhorses of Drug Discovery and Resistance

  2020cites this paper
• In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme

  2020cites this paper
• Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses

  2020cites this paper
• Making the family portrait complete: Synthesis of Electron Withdrawing Group activated Hoveyda-Grubbs catalysts bearing sulfone and ketone functionalities

  2020cites this paper
• Design, synthesis, and evaluation of a novel macrocyclic anti-EV71 agent.

  2020cites this paper
• Allosteric Regulation of SARS-CoV-2 Protease: Towards Informed Structure-Based Drug Discovery

  2020cites this paper
• Sulfone Mediated SNAr Reaction as a Powerful Tool for the Synthesis of 4-Quinolinyl Ethers and more - Application to the Synthesis of HCV NS3/4a Protease Inhibitor BI 201420.

  2020cites this paper
• Very-long-chain fatty acid metabolic capacity of 17-beta-hydroxysteroid dehydrogenase type 12 (HSD17B12) promotes replication of hepatitis C virus and related flaviviruses

  2020cites this paper
• On the cutting edge: protease-based methods for sensing and controlling cell biology

  2020cites this paper
• Dengue virus nonstructural 3 protein interacts directly with human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and reduces its glycolytic activity

  2019cites this paper
• Development and Marketing of INCIVEK (Telaprevir; VX-950): A First-Generation HCV Protease Inhibitor, in Combination with PEGylated Interferon and Ribavirin

  2019cites this paper
• The Evolution of Clinical Trials for Hepatitis C

  2019cites this paper
• In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.

  2019cites this paper
• GII.4 Norovirus Protease Shows pH-Sensitive Proteolysis with a Unique Arg-His Pairing in the Catalytic Site

  2019cites this paper
• Towards curative therapy of chronic viral hepatitis

  2019cites this paper
• The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir

  2019cites this paper
• Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs

  2019cites this paper
• Core–Shell‐Heterostructured Magnetic–Plasmonic Nanoassemblies with Highly Retained Magnetic–Plasmonic Activities for Ultrasensitive Bioanalysis in Complex Matrix

  2019cites this paper
• Identification of novel proteolytically inactive mutations in coronavirus 3C‐like protease using a combined approach

  2019cites this paper
• Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitor

  2019cites this paper
• HCV: The Journey from Discovery to a Cure: Volume II

  2019cites this paper
• The Invention of Grazoprevir: An HCV NS3/4a Protease Inhibitor

  2019cites this paper
• Zellkultursysteme als Basis der Therapieentwicklung für chronische Hepatitis C

  2019influential citation
• A comparison of machine learning algorithms for the prediction of Hepatitis C NS3 protease cleavage sites

  2019cites this paper
• Taming a beast: lessons from the domestication of hepatitis C virus.

  2019cites this paper
• Evolution of HCV NS3/4a Protease Inhibitors

  2019cites this paper
• Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands.

  2019cites this paper
• From Computers to Bedside: Computational Chemistry Contributing to FDA Approval

  2018cites this paper
• Green Process Chemistry in the Pharmaceutical Industry: Case Studies Update (2012–2016)

  2018cites this paper
• Exposure to hepatitis C virus early in life : Epidemiological and Immunological aspects

  2018cites this paper
• A review on HCV inhibitors: Significance of non-structural polyproteins

  2018cites this paper
• Evolution of efficacious pangenotypic hepatitis C virus therapies

  2018cites this paper
• Targeting Drug Resistance In HCV NS3/4A Protease: Mechanisms And Inhibitor Design Strategies

  2018cites this paper
• Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development

  2018cites this paper